Claims for Patent: RE34878

Summary for Patent: RE34878

Title:	Hypoglycemic agent
Abstract:	A compound of D-phenylalanine derivative for hypoglycemic use, represented by the general formula ##STR1## R1 is selected from hydrogen, alkyl of 1 to 5 carbon atoms, aryl of 6 to 12 carbon atoms, aralkyl of 6 to 12 carbon atoms, ##STR2## --CH2 CO2 R3, --CH(CH3)--OCO--R3, and --CH2 --OCO--C(CH3)3 ; R2 is selected from groups comprising aryl of 6 to 12 carbon atoms, a hetero six-membered ring, a hetero five-membered ring, cycloalkyl, or cycloalkenyl, any of which groups may have one or more substituents; and R3 is selected from hydrogen and alkyl of 1 to 5 carbon atoms; the salts thereof, and precursors which can be converted thereto in the human or animal body.Some of the compounds are novel per se.
Inventor(s):	Shigeshi Toyoshima, Yoshiko Seto, Hisashi Shinkai, Koji Toi, Izumi Kamashiro
Assignee:	Ajinomoto Co Inc
Application Number:	US08/157,564
Patent Claims:	1. A D-phenylalanine derivative of the formula R.sup.4 --CO--NR.sup.3 --CH(COOR.sup.1)--CH.sub.2 --C.sub.6 H.sub.5 or a salt thereof or a precursor which can be converted into said D-phenylalanine derivative in vivo, wherein: R1 is hydrogen or C1-5 alkyl, R.sup. is hydrogen or C1-5 alkyl; and R4 is cyclohexane substituted at the 4- or 5-position by methyl, ethyl, ispropyl, tert-butyl, ethene, or isopropene or cyclohexene substituted at the 4- or 5-position by methyl, ethyl, isopropyl, tert-butyl, ethene, or isopropene. 2. The D-phenylalanine derivative of claim 1, wherein R4 is said substituted cyclohexane. 3. The D-phenylalanine derivative of claim 1, wherein R4 is said substituted cyclohexane. 4. The D-phenylalanine derivative of claim 1, wherein the said derivative is N-(4-isopropylcyclohexylcarbonyl)-D-phenylalanine. 5. The D-phenylalanine derivative of claim 1, wherein the said derivative is N-(4-isopropylcyclohexylcarbonyl)-D-phenylalanine: N-[(S)-perilloyl]-D-phenylalanine; N-(4-methylcyclohexylcarbonyl)-D-phenylalanine; N-(4-ethylcyclohexylcarbonyl)-D-phenylalanine; or N-(4-t-butylcyclohexylcarbonyl)-D-phenylalanine. 6. The D-phenylalanine derivative of claim 1, wherein the said derivative is N-[(s)-perilloyl]-D-phenylalanine; N-(trans-4-methylcyclohexylcarbonyl)-D-phenylalanine; N-(trans-4-ethylcyclohexylcarbonyl)-D-phenylalanine; N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine; or N-(trans-4-t-butylcyclohexylcarbonyl)-D-phenylalanine. 7. The D-phenylalanine derivative of claim 1, wherein R1 is hydrogen and R3 is hydrogen. 8. The D-phenylalanine derivative of claim 1, wherein R4 is perilloyl. 9. The D-phenylalanine derivative of claim 1, wherein said substituted cyclohexane is substituted at the 4-position. 10. The D-phenylalanine derivative of claim 1, wherein said substituted cyclohexane is substituted at the 5-position. 11. The D-phenylalanine derivative of claim 1, wherein said substituted cyclohexene is substituted at the 4-position. 12. The D-phenylalanine derivative of claim 1, wherein said substituted cyclohexene is substituted at the 5-position. 13. The D-phenylalanine derivative of claim 1, wherein said substituted cyclohexane or said substituted cyclohexene is substituted with methyl, ethyl, isopropyl or tert-butyl. 14. The D-phenylalanine derivative of claim 1, wherein said substituted cyclohexane or said substituted cyclohexene is substituted by ethene, or isopropene. 15. A pharmaceutical composition, comprising a D-phenylalanine derivative of claim 1 and a pharmaceutical excipient. .Iadd.16. The compound N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine. .Iaddend.